Goldman Sachs has issued a ‘buy’ call on Neuland Laboratories, setting a target price of ₹12,975 per share. The recent US FDA approval for Bristol-Myers Squibb’s (BMS) schizophrenia drug, which involves Neuland Labs, is in line with Goldman Sachs’ expectations.
The approval has been highly anticipated, with US analysts recently expressing confidence in the likelihood of timely regulatory clearance. Now, the key points include the specific details of the FDA approval label, which will define the scope and usage guidelines for the drug.
Looking ahead, the commercial launch dynamics will come into focus, with revenue forecasts guided by Goldman Sachs’ US analysts. The potential for significant revenue growth from this drug is a key driver for the positive outlook on Neuland Labs.
Disclaimer: Stock market investments are subject to market risks. The information provided in this article is for informational purposes only and should not be construed as investment advice or a recommendation. Readers are advised to seek independent financial advice before making any investment decisions. The author and the publication are not responsible for any investment losses incurred based on the information provided.
